HDAC6 and acute lymphoblastic leukemia: This study therefore investigated the therapeutic potential of WT161, a selective HDAC6 inhibitor, focusing on its role in targeting of the VLA-4/Focal adhesion kinase (FAK) signaling pathway in ALL.